Inventaire - vos ami⋅e⋅s et communautés sont votre meilleure bibliothèque

In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma

auteur·ice

Amit Kumar Mitra

Li Chen

Shaji K Kumar

S. Vincent Rajkumar

Brian G Van Ness

publié dans: Blood Cancer Journal

date de publication: 2020-07-28

Articles cités 41

Date

Titre

Auteur·ices

2018-04-17

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.

Antonio Giovanni Solimando, Roberto Ria, Domenico Ribatti
2017-06-30

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

Shaji K Kumar
2017-09-27

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

M Kortüm, Patrick Jedlowski
2017-10-12

High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma

Kristian Bowles, Stuart A Rushworth
2017-01-12

The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.
2017-11-24

Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers

Stefan Habringer, Ulrich Keller
2017-03-31

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Brian A. Walker, Charlotte Pawlyn, Zoe Walters, Fabio Mirabella, Peter Bergsagel, Gareth J Morgan
2016-04-26

Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma

Li Zhang
2016-09-10

Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming
2016-01-01

miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF.
2016-04-13

Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
2015-11-13

Myeloma today: Disease definitions and treatment advances.
2015-12-02

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Monika Sopala, Ashraf Elghandour, Athanasios Dimopoulos, Sagar Lonial, Hermann Einsele, Philippe Moreau, Paul G. Richardson, Wiesław Jędrzejczak, Vania Hungria, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert Schlossman, Claudia Corrado, Bourras-Rezki Bengoudifa, Florence Binlich, Andreas Günther, Jesús San Miguel, Meral Beksac
2015-12-29

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

Alexej Abyzov, Shaji K Kumar
2015-08-21

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma

Jason S Gold
2015-05-26

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

Sagar Lonial
2014-10-26

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Jo Caers, Michele Cavo, Efstathios Kastritis, Hans Erik Johnsen, Giampaolo Merlini, Angela Dispenzieri, Athanasios Dimopoulos, Jesús San Miguel, Robert A Kyle, Sagar Lonial, Ola Landgren, Kenneth C. Anderson, Hartmut Goldschmidt, S. Vincent Rajkumar, Antonio Palumbo, Paul G. Richardson, Sonja Zweegman, Shaji K Kumar, Sundar Jagannath, Sigurdur Y Kristinsson, María Victoria Mateos, Evangelos Terpos, Brendan M Weiss, Jens Hillengass, Bruno Paiva, Elena Zamagni, Saad Z Usmani, Orhan Sezer, Joan Bladé, Juan José Lahuerta, Brian Durie, Meral Beksac
2014

pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels

Nancy J Cox
2014-06-01

microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics

Amelia Cimmino, Muller Fabbri
2014-03-01

Heat shock proteins in multiple myeloma

Jacqueline H L Fok, Faith E Davies
2013-03-27

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model

Susan Walsh, Michael A. Linden, John J Sunderland
2013-12-13

Causal analysis approaches in Ingenuity Pathway Analysis
2013-10-07

EZH2 in normal and malignant hematopoiesis

Mhairi Copland
2013-10

Chaperone machines for protein folding, unfolding and disaggregation

Helen Saibil
2013-04-04

The HSP70 family and cancer

Maureen Murphy
2012-04-26

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Yiguo Hu, Kenneth C. Anderson, Paul G. Richardson, Tanyel Kiziltepe, Hiroshi Ikeda, Naoya Mimura, Nikhil V Munshi, Mariateresa Fulciniti, Gullu T Gorgun, Diana D Cirstea, Anne-Claire Fabre, Hiroto Ohguchi
2011-04-11

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma

Jesús San Miguel, Paul G. Richardson, Kenneth C. Anderson, Jacob P Laubach, Constantine S Mitsiades, Faith E Davies
2011-06-28

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma

Wyndham H. Wilson
2011-06-30

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

Bin Zhou, Paul G. Richardson, Kenneth C. Anderson, Robert Z Orlowski, Noopur Raje, Dharminder Chauhan
2011-07-01

Potential role of heat shock proteins in neural differentiation of murine embryonal carcinoma stem cells (P19)

Marzieh Ebrahimi, Hossein Baharvand
2011-07-20

Molecular chaperones in protein folding and proteostasis

Franz-Ulrich Hartl
2011-05-31

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Frits van Rhee, Bart Barlogie, Sarah Waheed, Elias Anaissie

Article - wd:Q98158633

Bienvenue sur Inventaire

la bibliothèque de vos ami⋅e⋅s et communautés